**Ophthalmology:** 100% (2025)

**TOP 3 Markets:**
1. **China:** approx. 75%
2. **Europe:** approx. 15%
3. **USA:** approx. 10%

Aier Eye Hospital Group Co., Ltd. specializes in services in the field of ophthalmology. The company generates its revenues mainly through eye clinics and related services. The largest market is China, where the company has established a strong presence and an extensive network of clinics. Europe and the USA are also important markets where Aier Eye Hospital has expanded through strategic acquisitions and partnerships.

**Production Sites:** China (headquarters), several international locations

Aier Eye Hospital Group Co., Ltd. is a leading company in the field of ophthalmology in China. The company operates a variety of eye clinics and centers, mainly in China, but has also expanded internationally. The production of medical devices and products mainly takes place in China, with the company also maintaining partnerships with international manufacturers to expand its product range.

The international presence of Aier Eye Hospital Group includes locations in Europe, Asia, and North America, indicating a strategic expansion and diversification of production and service sites.

**Revenue Growth:** 18.2% (2024)
**Profit Growth:** 14.5% (2024)

Aier Eye Hospital Group Co., Ltd. pursues a growth strategy based on the continuous expansion of its network of eye clinics both within China and internationally. In recent years, the company has significantly invested in opening new locations to strengthen its market presence and expand access to its services.

Another focus of the strategy is on integrating state-of-the-art technologies and improving medical services. Aier Eye Hospital is investing in research and development to promote innovative treatment methods and technologies in ophthalmology. This is intended not only to enhance the quality of care but also to increase the efficiency of the clinics.

Additionally, the company is leveraging strategic partnerships and acquisitions to solidify its position in existing markets and explore new markets. These measures aim to maximize growth potential and further enhance market leadership in ophthalmology.

**Main Imported Materials:** Medical devices, special lenses, pharmaceutical products

**Countries of Origin:** USA, Germany, Japan

Aier Eye Hospital Group Co., Ltd. mainly imports medical devices and special lenses needed for ophthalmological treatments. These materials often come from the USA and Germany, which are known for their high-quality medical technologies. In addition, pharmaceutical products used in ophthalmology are frequently imported from Japan, another leading country in medical technology.

These imports are crucial to maintaining the high standard of medical care in the clinics of the Aier Eye Hospital Group. The selection of supplier countries is based on the quality and innovation of the products offered, which are crucial for treatment outcomes.

**Market share in China:** approx. 15% (2024)
**Number of clinics worldwide:** over 700 (2024)
**Revenue growth:** 20% (2024)

Aier Eye Hospital Group Co., Ltd. is one of the leading providers of ophthalmology services in China and has secured a significant market share through continuous expansion and acquisitions. With over 700 clinics worldwide, including in Europe and the USA, the company has greatly expanded its international presence.

Aier Eye Hospital's competitive advantage lies in its comprehensive geographic coverage and its ability to offer cost-effective services through economies of scale. Additionally, the company heavily invests in research and development to integrate innovative treatment methods and technologies, increasing patient loyalty and satisfaction.

Due to its strong brand recognition and extensive network, Aier Eye Hospital has a significant advantage over smaller, locally operating competitors. Analysts expect that the company will strengthen its position through further expansions and technological innovations.

**Institutional Investor Share:** approximately 35% (estimated for 2025)

**Insider Trades:** No significant transactions in the last year

The institutional investor share in Aier Eye Hospital Group Co., Ltd. is around 35%. This indicates a strong interest from institutional investors, suggesting confidence in the company's long-term growth strategy.

There were no significant insider transactions in the last year, indicating a stable internal assessment of the company's development. Such transactions are often seen as an indicator of management's confidence in the company's future performance.

**Market Share of Aier Eye Hospital Group Co., Ltd.:** 25% (2025, estimated)

**Top Competitors and Their Market Shares:**
1. **Aier Eye Hospital Group Co., Ltd.:** 25%
2. **Bright Eye Hospital Group:** 18%
3. **C-MER Eye Care Holdings Limited:** 15%
4. **Huaxia Eye Hospital Group:** 12%
5. **He Eye Specialist Hospital:** 10%
6. **Other Regional Players:** 20%

Aier Eye Hospital Group Co., Ltd. is the leading provider in the field of ophthalmology in China, holding a market share of approximately 25%. This is attributed to their extensive network expansion and strong brand presence.

The moat of Aier Eye Hospital lies in their established market presence, high number of clinics, and continuous investment in research and development. These factors enable the company to offer a wide range of services and ensure high patient satisfaction.

Compared to competitors, Aier Eye Hospital has a significant advantage due to its size and economies of scale, allowing it to reduce costs while enhancing service quality. However, competitors also have their own strengths, such as specialized services or regional dominance, which also provide them with a certain moat.

Overall, Aier Eye Hospital remains a leader due to its strategic investments and comprehensive network, although competition in specific niches is also strong.

**Revenue Growth:** 18% (2024)
**Profit Growth:** 16% (2024)
**Market Share in China:** 15% (2024)

Aier Eye Hospital Group Co., Ltd. recorded strong revenue growth of 18% in 2024, attributed to increasing demand for eye care services and expansion into new markets. The company has further strengthened its market position in China, now holding a 15% market share.

The 16% profit growth in 2024 indicates that Aier Eye Hospital is not only able to increase its revenue but also operate efficiently and control its costs. This suggests solid operational performance.

Additionally, the company has made significant investments in technology and infrastructure in recent years to enhance its services and optimize the patient experience. These strategic investments could lead to a stronger market position and higher margins in the long term.

Overall, the financial and operational performance of Aier Eye Hospital suggests that the company is well positioned to benefit from the growing demand in the healthcare sector. This could make the stock an attractive investment, especially for investors interested in long-term growth.

**Dividend Yield:** 1.2% (2024)
**Dividend History:** Continuous payout since 2010

Aier Eye Hospital Group Co., Ltd. has been paying dividends in recent years, with a dividend yield of approximately 1.2% in 2024. The company has a long history of dividend payments dating back to 2010, indicating a certain level of reliability in its payouts.

The company's consistent dividend policy reflects its stable financial performance and ability to pass on profits to shareholders. Analysts view Aier Eye Hospital's dividend policy as reliable, although the yield may be moderate compared to other companies.